Evonile Pharma Limited

This is a regulatory disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, informing the exchange of the outcomes from the Board of Directors meeting held on October 08, 2026.

Key Matters Approved

1. Approval for Raising of Funds by way of Rights Issue

The Board approved raising funds through the issuance and allotment of partly paid-up equity shares.

  • Security Type: Equity shares with a face value of ₹5 each.
  • Maximum Aggregate Amount: ₹9,000 million (Rupees Nine Thousand Million only).
  • Basis of Issue: Rights issue to eligible equity shareholders as on a record date to be determined and notified later.
  • Approvals Required: The issue is subject to receipt of applicable statutory and regulatory approvals.
  • Governing Regulations: The issue will be conducted in accordance with the Companies Act, 2013, the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, the SEBI Listing Regulations, and other applicable laws.
2. Constitution of Rights Issue Committee

The Board approved the constitution of a Rights Issue Committee with the following members:

  • Mr. Vikas Gupta – Managing Director and Chief Executive Officer
  • Dr. Jagriti Gupta – Non Executive Director
  • Mr. Shashank Sinha – Independent Director

This committee has been delegated the authority to determine and finalize the detailed terms and conditions of the Rights Issue, including but not limited to:

  • Issue size
  • Rights entitlement ratio
  • Issue price
  • Record date
  • Timing of the issue
  • Allotment of shares
  • Appointment of intermediaries
3. Approval of Postal Ballot Notice

The Board approved the notice of a Postal Ballot for seeking the approval of the company's shareholders for the proposed matters.

4. Adoption of New Corporate Website

The Board approved the adoption and launch of a new corporate website for the company under its new name, Evonile Pharma Limited. The website address is www.evonilepharma.com.

Meeting Details

The Board meeting commenced at 04:40 PM IST and concluded at 5:31 PM IST on October 08, 2026.

Additional Information

The disclosed information will also be available on the company's new website at www.evonilepharma.com.

Annexure A Details (Regulation 30 Requirements)

  • Type of securities proposed to be issued: Equity Shares (Partly paid-up)
  • Type of issuance: Rights Issue
  • Total number/amount of securities: Issue for an aggregate amount not exceeding ₹9,000 Million. The number of securities, price, and terms will be decided by the Board or the Rights Issue Committee at a later date.
  • Cancellation/Termination: Not Applicable